Indian Journal of Private Psychiatry

Register      Login

VOLUME 12 , ISSUE 1 ( January-June, 2018 ) > List of Articles

CASE REPORT

Two Cases of Blonanserin Induced Dyskinesia

Dhananjay Chaudhari, Ganesh Shanker, Kunjan Gupta

Keywords : Dyskinesia, Tardive Dyskinesia,Blonanserin

Citation Information : Chaudhari D, Shanker G, Gupta K. Two Cases of Blonanserin Induced Dyskinesia. Ind J Priv Psychiatry 2018; 12 (1):29-30.

DOI: 10.5005/jp-journals-10067-0015

License: CC BY-ND 3.0

Published Online: 00-06-2018

Copyright Statement:  Copyright © 2018 Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Blonanserin is an atypical antipsychotic with favorable outcome especially for negative symptoms of schizophrenia, and it also has some beneficial effects on cognition. It is well known that atypical antipsychotics have favorable adverse effect profile as compared to typical and conventional antipsychotics. As blonanserin is a relatively newer compound, so there is dearth of studies related to its side effect profile. Here we are reporting two cases of blonanserin induced dyskinesia.


PDF Share
  1. Daniel DG, Egan MF, Wolf SS. Neuropsychiatric aspects of movement disorders. In: Comprehensive Textbook of Psychiatry. 7th ed. Lippincott Williams & Wilkins, Philadelphia, USA; 2000.
  2. Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y) 2013;12:3.
  3. Gebhardt S, Härtling F, Hanke M, et al. Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment. Eur Child Adolesc Psychiatry. 2006 Oct;15(7):371-382.
  4. Lonansen ® (Blonanserin): prescribing information. Osaka: Dainippon Sumitomo Pharma Co. Ltd; 2009.
  5. Peña MS, Yaltho TC, Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord. 2011;26:147-152.
  6. Une T, Kurumiya S. Pharmacological profile of blonanserin. Jpn J Clin Psychopharmacol. 2007;10(7):1263-1272.
  7. Miyamoto S, Fleischhacker WW, Lieberman JA. Pharmacologic treatment of schizophrenia. In: Lieberman JA, Murray RM, editors. Comprehensive Care of Schizophrenia (Second Edition): A Textbook of Clinical Management. New York: Oxford University Press; 2012. pp. 77-138.
  8. Deeks ED, Keating GM. Blonanserin: a review of its use in the management of schizophrenia. CNS Drugs. 2010;24(1):65-84.
  9. Oka M, Noda Y, Ochi Y, et al. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J Pharmacol Exp Ther. 1993;264(1):158-165.
  10. Miura S. Clinical evaluation of blonanserin for schizophrenia: a randomized study comparing blonanseria with risperidone. Jpn J Clin Psychopharmacol 2008;11:297-314.
  11. Murasaki M. Clinical evaluation of blonanserin for schizophrenia: a double-blind trial comparing blonanserin with haloperidol. Jpn J Clin Psychopharmacol 2007;10: 2059-2079.
  12. Saraswathy GR, Virupaksha HS, et al. Blonanserine induced hypokinesia and Tardive Dyskinesia. J Mol Biomark Diag. 2015;6(6):254.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.